Particularly, our data support the development of further ex vivo and in vivo experiments combining TRAIL-receptor agonists with compounds inhibiting TRAIL-induced pro-survival signals (e.g MAPK inhibitors) to evaluate the possibility of boosting TRAIL-induced cancer-selective death while inhibiting its tumor-promoting features. The gene discussed is TNFSF10; the disease is cancer.